Investor Relations > details

Zensun Completed Chinese Phase II Clinical Study of rhNRG-1


Zensun accomplished Chinese phase II clinical trial of rhNRG-1—Zensun’s proprietary anti-heart failure drug.

During the past two years, Zensun conducted randomized, double-Blind, multi-center, placebo-controlled phase II clinical studies in over 30 hospitals nationwide. The initial statistics show that the heart function was improved effectively with rhNRG-1 treatment.

In May 21st, 2009, Zensun held press conference in Zhangjiang, Shanghai and claimed phase II clinical study report in China and Australia to the media worldwide.